Verastem, Inc. Liabilities, Fair Value Adjustment
Verastem, Inc. (VSTM) reported Liabilities, Fair Value Adjustment of $1.31 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-18.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
us-gaap:LiabilitiesFairValueAdjustment · last filed 2021-03-18
- Verastem, Inc. liabilities, fair value adjustment for fiscal 2020 was $1.31M, a 104.84% increase from fiscal 2019.
- Verastem, Inc. liabilities, fair value adjustment for fiscal 2019 was $641.00K.
- Verastem, Inc. liabilities, fair value adjustment for fiscal 2018 was -$25.56M.
| Period end | Liabilities, Fair Value Adjustment 12 month | Liabilities, Fair Value Adjustment 12 month as first filed |
|---|---|---|
| 2020-12-31 | $1.31M 10-K · filed 2021-03-18 | |
| 2019-12-31 | $641.00K 10-K · filed 2021-03-18 | |
| 2018-12-31 | -$25.56M 10-K · filed 2020-03-11 | -$25.56K 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |